Assembly Biosciences (NASDAQ:ASMB) Announces Earnings Results

Assembly Biosciences (NASDAQ:ASMB) released its earnings results on Thursday. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.11, Zacks reports. Assembly Biosciences had a negative return on equity of 4.70% and a negative net margin of 8.98%.The firm had revenue of $8.21 million for the quarter, compared to analysts’ expectations of $9.27 million.

Assembly Biosciences Price Performance

Shares of ASMB traded down $1.19 during trading hours on Friday, hitting $29.74. 143,418 shares of the stock were exchanged, compared to its average volume of 141,040. Assembly Biosciences has a fifty-two week low of $11.64 and a fifty-two week high of $39.71. The business has a 50-day moving average of $28.67 and a 200-day moving average of $30.55. The firm has a market capitalization of $472.57 million, a P/E ratio of -270.34 and a beta of 1.08.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Monday, April 20th. Wall Street Zen raised Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Sunday, March 29th. Guggenheim lifted their price target on Assembly Biosciences from $39.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, April 6th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a research note on Monday. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.75.

Institutional Investors Weigh In On Assembly Biosciences

Several large investors have recently added to or reduced their stakes in the business. RA Capital Management L.P. acquired a new stake in Assembly Biosciences during the third quarter worth approximately $26,122,000. Janus Henderson Group PLC boosted its stake in Assembly Biosciences by 11.3% during the fourth quarter. Janus Henderson Group PLC now owns 837,925 shares of the biopharmaceutical company’s stock worth $28,540,000 after acquiring an additional 85,299 shares in the last quarter. Paradigm Biocapital Advisors LP bought a new position in Assembly Biosciences during the fourth quarter worth $22,625,000. Vanguard Group Inc. boosted its stake in Assembly Biosciences by 97.8% during the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after acquiring an additional 248,287 shares in the last quarter. Finally, Parkman Healthcare Partners LLC bought a new stake in Assembly Biosciences in the third quarter valued at $6,425,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.